What Is the Best Medicine to Lose Weight?

Tirzepatide (sold as Mounjaro and Zepbound) produces more weight loss than any other approved medication, outperforming the better-known semaglutide (Ozempic, Wegovy) by a meaningful margin in head-to-head studies. But “best” depends on more than raw pounds lost. Your diabetes status, cardiovascular history, tolerance for side effects, willingness to inject weekly for years, and budget all shape which drug actually works best for you. The landscape of weight-loss medications has shifted dramatically since 2021, and a still-newer generation of drugs in late-stage trials may reset the rankings again soon.

Tirzepatide vs. Semaglutide, Head to Head

The two dominant prescription options right now are both weekly injections. Semaglutide targets one gut hormone receptor (GLP-1). Tirzepatide targets two (GLP-1 and GIP). That dual action translates into consistently larger weight reductions. A systematic review and meta-analysis of clinical trials and real-world data found that tirzepatide produced roughly 4 kg more weight loss than semaglutide overall, and the gap widened at higher doses and longer durations. At doses above 10 mg, tirzepatide’s advantage grew to about 6.5 kg more than semaglutide.¹

Real-world data from a large cohort study echoed the trial results. Patients on tirzepatide were about three times as likely to reach the 15% weight-loss threshold compared to those on semaglutide. By 12 months, the difference in percentage of body weight lost was nearly 7 percentage points in tirzepatide’s favor.² A separate meta-analysis focused on people with type 2 diabetes found a similar pattern: tirzepatide users averaged about 11% body-weight loss versus roughly 7% for semaglutide users across direct comparison studies.³

So if raw efficacy is your sole criterion, tirzepatide is the current frontrunner among approved drugs. That said, semaglutide has a far deeper evidence base for outcomes beyond weight. Its cardiovascular trial data, discussed below, are something tirzepatide does not yet match.

Older Options Still on the Table

Not everyone needs or can access the newest injectable drugs. Two older medications remain approved and still see wide use.

Phentermine/topiramate (Qsymia) combines a stimulant appetite suppressant with an anticonvulsant. It is a daily pill, not an injection, and costs considerably less than the newer drugs. A meta-analysis of trials found it produced an average of about 8 kg of weight loss at its highest dose compared to placebo, with the mid-range dose coming in around 7 kg.⁴ A phase 3 trial showed that about 70% of people on the higher dose lost at least 5% of their body weight, and roughly half lost 10% or more.⁵ Those numbers are respectable, though smaller than what the newer injectables achieve. The side effects are distinct from the GLP-1 drugs: tingling sensations, dry mouth, altered taste, constipation, dizziness, and occasionally mood changes including anxiety or depression.⁵ For people at low-to-intermediate cardiovascular risk, the cardiovascular safety profile appears acceptable.⁶

Orlistat (Xenical, or the lower-dose over-the-counter Alli) takes a completely different approach. It blocks roughly 30% of the fat you eat from being absorbed, which works out to about 200 fewer calories per day at standard doses.⁷ The weight loss is modest compared to newer drugs. Orlistat’s side effects are almost entirely gastrointestinal and directly tied to how much fat you eat: oily stools, urgency, and flatulence. Many people find these side effects intolerable, which is part of why orlistat has fallen out of favor as more effective options have appeared. It remains the only weight-loss drug available without a prescription (at the lower dose), so it fills a niche for people who cannot or choose not to pursue other medications.

What Is Coming Next

A third generation of drugs is in late-stage clinical trials, and early data suggest they will push weight-loss numbers even higher. The most talked-about is retatrutide, a triple-receptor agonist that targets GLP-1, GIP, and glucagon receptors simultaneously. In a phase 2 trial, participants on the highest dose lost an average of about 24% of their body weight over 48 weeks, far exceeding what either semaglutide or tirzepatide typically achieve.⁸ Retatrutide also showed dramatic improvements in liver fat, with one analysis reporting an 82% reduction in fatty liver in trial participants, along with improvements in blood pressure, cholesterol, and waist circumference.⁹ Phase 3 trial results are still pending, so retatrutide is not yet approved for prescription.

Another significant development is orforglipron, a once-daily pill that activates the same GLP-1 receptor targeted by semaglutide but is a small molecule rather than a peptide. That distinction matters because peptide drugs require injection; orforglipron can be swallowed. A phase 2 trial found that higher doses produced around 15% body-weight loss by 36 weeks.¹⁰ Longer phase 3 data at 72 weeks showed the top dose achieved about 11% weight loss, with over a third of participants losing 15% or more of their body weight.¹¹ Those results fell somewhat below the injectable drugs, but an effective daily pill could vastly expand access for people who refuse or cannot manage weekly injections. In adults with type 2 diabetes, the highest dose produced about 10% weight loss over 72 weeks.¹²

Why Diabetes Status Changes the Answer

One of the strongest predictors of how much weight you lose on any GLP-1-based drug is whether you have type 2 diabetes. People without diabetes consistently lose substantially more weight on the same medication. A narrative review found that the gap between drug and placebo in people with diabetes was roughly 4 to 6 percentage points of body weight, while in people without diabetes it was 6 to 17 percentage points.¹³ A large analysis quantified this more starkly: people without diabetes lost about 16% of their body weight at 12 months, versus about 5% in people with diabetes on the same agents. Diabetes status emerged as a strong independent negative predictor of weight loss.¹⁴

The reasons are not fully settled, but the insulin resistance that characterizes type 2 diabetes likely blunts some of the metabolic pathways these drugs exploit. If you have diabetes, the medications still work, but setting expectations is important: a 5-8% weight loss may be a realistic and still clinically meaningful outcome for you, rather than the 15-20% figures that make headlines in trials of non-diabetic participants.

Cardiovascular and Organ-Level Benefits

Weight loss alone does not explain all the benefits these drugs provide. The SELECT trial, one of the largest cardiovascular outcome trials ever run for a weight-loss drug, showed that semaglutide reduced major cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% in people with obesity and established heart disease but without diabetes.¹⁵ That benefit held regardless of how much weight a person started at or how much their waist circumference changed, suggesting that some of the cardiovascular protection is independent of weight loss itself.¹⁶

Kidney protection is another area of growing evidence. Across trials, GLP-1 drugs reduced a composite kidney outcome by roughly 17-21%, though most of that benefit came from reducing protein leakage into the urine rather than slowing the progression to kidney failure itself.¹⁷

Fatty liver disease is perhaps where these drugs show some of their most striking effects. A meta-analysis found that GLP-1 drugs tripled the odds of resolving inflammatory liver disease (MASH) without worsening liver scarring.¹⁸ In patients with moderate-to-advanced liver scarring, GLP-1 drugs also improved fibrosis scores.¹⁹ Among the newer agents, tirzepatide appears to have somewhat more robust evidence for liver improvement than semaglutide or older GLP-1 drugs, and early retatrutide data look even more impressive for liver fat reduction.²⁰ These organ-level benefits matter when choosing between medications: if you have fatty liver disease or existing heart disease, semaglutide or tirzepatide may offer protective effects that go well beyond the number on the scale.

Side Effects and Safety Concerns

Every weight-loss medication comes with trade-offs, and the GLP-1-based drugs share a common set of gastrointestinal side effects: nausea, vomiting, diarrhea, and constipation. These are most common during the early dose-escalation phase and typically improve over weeks to months. Gradual dose increases are the standard strategy for minimizing their severity.²¹

Rarer but more serious gastrointestinal risks exist. A pharmacoepidemiologic study comparing GLP-1 drugs to another weight-loss medication (bupropion-naltrexone) found that GLP-1 users had higher rates of pancreatitis, bowel obstruction, and gastroparesis (delayed stomach emptying).²² Gallstone formation also appears at elevated rates, particularly in trials with rapid or large weight loss. In the adolescent semaglutide trial, 4% of semaglutide-treated teens developed gallstones, versus none on placebo.²³

Mental health has received significant attention. One retrospective database study flagged a near doubling of psychiatric disorder diagnoses in GLP-1 users, including elevated rates of depression, anxiety, and suicidal behavior.²⁴ However, the largest subject-level analysis of actual clinical trial data, pooling participants across multiple GLP-1 development programs, found no increased risk of suicidal ideation or behavior compared to placebo. The rates in both groups were identical, and risks for anxiety, depression, and psychosis were similarly not elevated.²⁵ The discrepancy likely reflects the difference between retrospective database studies, which cannot control for the fact that people seeking obesity treatment already have higher baseline psychiatric risk, and randomized trials that directly compare drug to placebo. The clinical trial evidence is more reassuring, but anyone with a history of mood disorders should discuss this with their prescriber.

What Happens When You Stop

This is the uncomfortable reality that often gets buried beneath the weight-loss headlines. These drugs treat obesity as a chronic condition, and stopping treatment reliably leads to weight regain. A systematic review with meta-regression modeling found that one year after stopping a GLP-1 drug, people had regained about 60% of the weight they lost during treatment. The trajectory eventually plateaus, but the estimated ceiling is regaining roughly 75% of the lost weight.²⁶ Among individual drugs, semaglutide showed the highest absolute regain after discontinuation, which makes sense given that it produces large losses in the first place, meaning there is more to regain.²⁷

This pattern has practical implications. Most people who benefit from these medications will need to stay on them long-term, which has obvious cost and access consequences. It also means that choosing a medication you can tolerate and afford indefinitely matters more than chasing the one with the absolute highest peak weight loss.

Exercise as a Partner, Not a Replacement

Adding structured exercise to a GLP-1 drug does not just add a little extra weight loss. It appears to change the kind of weight you lose and how well the benefits stick. A randomized trial found that combining exercise with liraglutide (an older GLP-1 drug) reduced abdominal fat by about six percentage points, roughly double what either exercise or liraglutide achieved alone, and it was the only group that saw a significant drop in a key marker of inflammation.²⁸ After treatment ended, people who had combined exercise with the drug kept significantly more weight off and maintained a lower body-fat percentage one year later compared to those who had used the drug alone.²⁹

Exercise may also protect bone health during weight loss. Semaglutide treatment has been associated with small but measurable declines in bone mineral density at the hip, spine, and tibia, similar to the bone loss seen with any calorie restriction.³⁰ In the combination trial, people who exercised alongside the drug showed no significant bone density change at the hip or spine, suggesting that exercise may buffer the bone-thinning effect.³¹

The Muscle-Loss Question

Any time you lose a large amount of weight quickly, some lean tissue goes with it. This has generated widespread worry about GLP-1 drugs causing dangerous muscle wasting. The evidence is more nuanced than the alarm suggests. A meta-analysis found that GLP-1 drugs led to a substantial 17% decline in fat mass but only about a 1-2% reduction in lean body mass. Skeletal muscle mass declined modestly, and the relative skeletal muscle index (muscle mass adjusted for height) did not change significantly.³²

There is real variability across individual studies, with some reporting lean mass losses of 40-60% of total weight lost and others showing losses of 15% or less of total weight lost.³³ A review using MRI-based measurements offered a more optimistic interpretation: the muscle changes seen with GLP-1 drugs appear to be proportionate to the weight lost, similar to what happens with any weight-loss method. Improvements in insulin sensitivity and reductions in fat infiltration within the muscle itself may actually improve muscle quality, even as absolute muscle volume decreases.³⁴ Resistance training is widely recommended as a countermeasure, and the exercise data above suggest it helps preserve both muscle and bone.

Weight-Loss Drugs in Adolescents

Semaglutide is approved for use in adolescents aged 12 and older with obesity. In the single large randomized trial completed so far, teens on semaglutide had an average BMI reduction of about 16% over 68 weeks, compared to a slight increase on placebo. About 73% achieved at least 5% weight loss.²³ Gastrointestinal side effects were more common with the drug (62% vs. 42% on placebo), and gallstone formation occurred in a small percentage. Blood sugar, liver enzymes, cholesterol, and quality of life all improved.³⁵ The big caveat is that long-term safety data in adolescents are extremely limited. There is only one large trial so far, and the effects on growth, bone development, and psychological well-being over years remain open questions.

Compounded Versions and Access Traps

Shortages and high costs have driven many people toward compounded versions of GLP-1 drugs, prepared by compounding pharmacies rather than the original manufacturer. These products are not subject to the same quality testing as FDA-approved formulations, and safety data from the FDA’s adverse event reporting system show higher rates of reported problems including nausea, abdominal pain, gallbladder inflammation, prescribing and preparation errors, and hospitalizations compared to the brand-name versions.³⁶ Dosing variability is a particular concern because these drugs are escalated gradually and even small differences in concentration can shift you from the therapeutic window into a range that causes severe side effects. The cost savings are real, but the risk trade-off is not trivial.

Reward Pathways and Unexpected Effects on Cravings

Researchers have increasingly noted that GLP-1 drugs appear to dampen cravings beyond just food. GLP-1 receptors are present in brain regions that govern reward and addiction, including areas involved in dopamine signaling. Preclinical studies show these drugs reduce intake and relapse-like behavior across a range of substances including alcohol, nicotine, and cocaine, and early-phase human trials suggest potential efficacy in reducing craving for some of these substances.³⁷ This is still early science, and no GLP-1 drug is approved for addiction treatment. But many patients anecdotally report reduced interest in alcohol or compulsive eating behaviors, and the neurobiological explanation is becoming clearer. Whether this effect persists after stopping the drug, or whether it might eventually justify prescribing these drugs for addiction independently of weight, remains to be seen.

Cost and the Question of Who Gets Access

The practical answer to “what is the best medicine to lose weight” is constrained by price for most people. In the United States, the list price for semaglutide and tirzepatide hovers around $1,000 per month or more, and insurance coverage is inconsistent. A cost-effectiveness analysis of semaglutide found that over a 30-year horizon, the cost per quality-adjusted life year gained ranged widely depending on the comparator, from roughly $24,000 to over $144,000.³⁸ At the lower end, that falls within conventional thresholds most health economists consider acceptable. But those models assume long-term continuous use, and many insurance plans still treat obesity drugs as elective.

The arrival of oral options like orforglipron could eventually shift the economics. Small-molecule pills are generally cheaper to manufacture than injectable peptides, and competition in the space is intensifying. For now, though, the gap between what works best on paper and what a given person can actually obtain and afford remains wide. Phentermine/topiramate, at a fraction of the cost, still produces meaningful weight loss and may be the most realistic option for many people, particularly those without diabetes or cardiovascular disease who simply need help losing 5-10% of their body weight.